[Experience of using three phosphodiesterase type 5 inhibitors in the same period for the treatment of erectile dysfunction].
OBJECTIVE
To observe and compare the effects and adverse events of the three phosphodiesterase type 5 (PDE-5) inhibitors sildenafil, vardenafil and tadalafil used in the same period for the treatment of erectile dysfunction (ED).


METHODS
A total of 311 ED patients were treated with the three PDE-5 inhibitors in the same period, 134 with sildenafil, 109 with vardenafil and 88 with tadalafil, and followed up for 2-11 months. Their effects were compared.


RESULTS
Sildenafil produced satisfactory effect in 72 patients (79.12%), vardenafil in 63 (81.81%) and tadalafil in 52 (78.78%), respectively. And the efficacy rates of sildenafil, vardenafil and tadalafil in the treatment of ED with premature ejaculation were 55.56%, 44.44% and 42.3%, respectively. Our study also showed that the young and the newly married preferred vardenafil, the middle-aged chose tadalafil and the older and long-term users tend to take sildenafil. The main reasons for discontinuing the use of the three inhibitors were their high price, incomplete effect and the patients' worry about their adverse action.


CONCLUSIONS
The three PDE-5 inhibitors can produce basically similar effects on ED, all with safety and few mild adverse events.
Zhang
Si-xiao
SX
Department of Urology, Huaxi Hospital, Sichuan University, Chengdu, Sichuan 610041, China.
Gao
Ping
P
D000328:Adult; D007172:Erectile Dysfunction / Q000188:drug therapy*; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D058986:Phosphodiesterase 5 Inhibitors; D010726:Phosphodiesterase Inhibitors / Q000008:administration & dosage*
D058986:Phosphodiesterase 5 Inhibitors; D010726:Phosphodiesterase Inhibitors